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Abstract
Heart valve endothelial cells (VECs) are distinct from vascular endothelial cells (ECs), but have an 
uncertain context within the spectrum of known endothelial phenotypes, including lymphatic 
endothelial cells (LECs). Profiling the phenotypes of the heart valve surface VECs would facilitate 
identification of a proper seeding population for tissue engineered valves, as well as elucidate 
mechanisms of valvular disease. Porcine VECs and porcine aortic ECs (AECs) were isolated from 
pig hearts and characterized to assess known EC and LEC markers. A transwell migration assay 
determined their propensity to migrate toward VEGF, an angiogenic stimulus, over 24 hours. 
Compared to AECs, Flt-1 was expressed on almost double the percentage of VECs, 74% vs. 38%. 
Expression of angiogenic EC markers CXCR4 and DLL4 was >90% on AECs whereas VECs 
showed only 35% CXCR4+ and 47% DLL4+. AECs demonstrated greater migration (71.5±11.0 
cells/image field) than did the VECs with 30.0±15.3 cells/image field (p=0.032). 30% of VECs 
were positive for LYVE1+/Prox1+, while these markers were absent in AECs. In conclusion, the 
population of cells on the surface of heart valves is heterogeneous, consisting largely of non-
angiogenic VECs and a subset of LECs. Previous studies have indicated the presence of LECs 
within the interior of the valves, however this is the first study to demonstrate their presence on the 
surface. Identification of this unique endothelial mixture is a step forward in the development of 
engineered valve replacements as a uniform EC seeding population may not be the best option to 
maximize transplant success.
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Introduction
Valvular endothelial cells (VECs) have been identified to have distinct differences in 
biomechanical responses and gene expression in comparison to endothelial cells found in the 
vascular system. Among the earliest observations that distinguish the biomechanical 
responses of VECs from that of vascular endothelial cells (ECs) was their perpendicular 
alignment to the direction of flow, contrary to the parallel cell alignment characteristic of 
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vascular ECs (Deck 1986, Butcher et al. 2004). While both cell types express similar 
antioxidant and anti-inflammatory genes, VECs were found to demonstrate lower expression 
of inflammatory-related genes than did vascular ECs (Butcher et al. 2004, Butcher et al. 
2006). Additionally, VECs expressed more genes related to cartilage formation, whereas 
vascular ECs had greater expression of genes involved in bone formation (Butcher et al. 
2006). One of the key differences between cartilage and bony tissues is their vascularization; 
cartilage tissues are primarily avascular, whereas bone tissues are highly vascularized and in 
fact require angiogenesis for bone formation. These comparative results suggest that VECs 
perform a protective role against calcification (Puperi et al. 2015, Wiltz et al. 2013), even 
within their dynamic shear stress environment, and that they may not readily express genes 
for angiogenesis.
Furthermore, even though confluent VEC cultures can demonstrate the cobblestone 
appearance typical of EC monolayers, VECs appear to be much more sensitive to the 
presence of various proteins than would be observed in other EC cultures. For example, 
chemokines transforming growth factor β and tissue necrosis factor α (TNF-α) have both 
been shown to induce VECs to express a mesenchymal phenotype (elongated, instead of 
cobblestone), to express α-smooth muscle actin (αSMA), an interstitial marker, and to 
reduce VEC expression of CD31 (Paranya et al. 2001, Paruchuri et al. 2006, Mahler et al. 
2013, Farrar and Butcher 2014). Therefore, this particular process results in the VECs taking 
on traits characteristic of valve interstitial cells (VICs), which are located in the interior of 
the valve. This complex biochemical process has been studied in detail, with reports 
describing some heterogeneity in VEC transdifferentiation responses to various chemokines 
(Paranya et al. 2001, Paruchuri et al. 2006, El-Hamamsy et al. 2010, Farrar and Butcher 
2014). In addition, previous gene analysis comparisons of VECs isolated from the outflow 
aortic side to the inflow side of valve leaflets have identified side specific differences in 
VEC expression for various calcification inhibitors, suggesting that there is heterogeneity in 
VEC phenotype (Simmons et al. 2005). Another type of phenotypical heterogeneity is 
addressed in this study. Despite the observed phenotypic differences between VECs and 
vascular ECs, little work has been done to characterize where VECs fit in the spectrum of 
known endothelial cell behavioral subpopulations. Comparing VECs to known EC 
phenotypes serves to provide a frame of reference for potential differentiation studies needed 
in the future to provide an EC population similar to VECs for tissue engineering 
applications.
Vascular ECs can be generally categorized into three phenotypes: tip, stalk, and phalanx. 
Here, these populations will be referred to as angiogenic ECs and non-angiogenic ECs. 
Angiogenic ECs (tip/stalk) are stimulated by a chemical signal, usually vascular endothelial 
growth factor (VEGF) (Gerhardt et al. 2003), to begin migration, proliferation, and sprout 
formation towards the source of the signal. However, the more recently identified non-
angiogenic ECs (phalanx) do not respond in the same manner, preferring to remain in the 
lumen of the parent vessel (Mazzone et al. 2009, Blancas et al. 2012). Since the VEC layer 
in normal valves also appears to be generally non-migratory (Chalajour et al. 2004), the 
potential for similarity between VECs and non-angiogenic ECs merits investigation.
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Previous studies have shown that the ECs located in the interior of normal heart valves 
(within the leaflet as opposed to the surface) contain a population of lymphatic endothelial 
cells (LECs) (Johnson and Blake 1966, Kholová et al. 2013). In pathological conditions, 
there is an increase of angiogenesis as well as lymphangiogenesis within the valves, possibly 
in response to a variety of inflammatory signals (Kholová et al. 2011, Kholová et al. 2013). 
However, it is unknown whether the LECs are restricted to the interior of the valve, or if 
there is a population on the outside of the valve leaflets as well.
Therefore, the purpose of this study was to characterize the population of VECs cultured 
from the surface of aortic valves with respect to a broad range of EC phenotypes, including 
angiogenic, non-angiogenic, and lymphatic.
Materials and Methods
Cell isolation and purification
VECs were harvested from aortic valve leaflets and aortic endothelial cells (AECs) from 
aortic root tissues dissected from fresh porcine adult hearts (6 months old). Tissues were 
purchased from commercial abattoirs Fisher Ham and Meats (Spring, TX) and Animal 
Technologies (Tyler, TX). After dissection, tissues were digested in a collagenase II/dispase 
solution for 1 hr at 37°C to loosen the ECs. Next, VECs and AECs were gently scraped from 
the surface of valve leaflets and the lumen of aortic tissues, respectively. The collected cells 
were then cultured on gelatin-coated flasks in EGM-2 basal growth media with bullet kit 
(Lonza, Walkersville, MD) plus 1% penicillin/streptomycin (Lonza). At passage P1, isolated 
endothelial cells were purified for CD31+ populations using CD31 antibody (Millipore, 
Temecula, CA) conjugated-CELLection magnetic sorting beads (Invitrogen/Life 
Technologies, Carlsbad, CA). Cells were sorted once when freshly isolated, and once more 
if thawed from frozen stock. VECs were used between passages P1–P5, and AECs were 
used between passages P1–P6.
Flow cytometry analysis
VECs and AECs were analyzed via flow cytometry for various EC and LEC markers. Cells 
were harvested using Cell Dissociation Buffer (LifeTechnologies) and fixed in 4% 
formaldehyde for 1 hr at 4°C. For intracellular staining, cells were additionally treated with 
ice-cold methanol (−20°C) for 1 hr at 4°C. Primary antibodies for EC markers CD31 
(MCA1746 clone LCI-1, AbD serotec, Raleigh, NC), and Flt-1 (sc-31173 clone N-16, Santa 
Cruz, Dallas, TX), tip-cell/angiogenesis related markers CXCR4 (ab2074, Abcam, 
Cambridge, MA) and DLL4 (ab7280, Abcam), and lymphatic markers Prox1 (ab33219 
clone 5G10, Abcam) and LYVE1 (ab33682, Abcam) were all used at a concentration of 1 μg 
per million cells in a staining buffer containing 1% bovine serum albumin (BSA) in 
phosphate buffered saline (PBS). Primary antibody incubation occurred at RT for 30 min, 
with agitation using a vortex at 15 min. Secondary antibodies conjugated with AlexaFluor 
488/647 (Invitrogen/Life Technologies and Abcam) were also used at 1 μg per million cells 
in a staining buffer containing 1 % BSA in PBS. Secondary antibody incubation occurred at 
RT for 30 min, with agitation using a vortex at 15min. All samples (n=3–6 biological 
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replicates) were run on a BD FACSCantoII (Franklin Lakes, NJ) and analyzed using FlowJo 
software (FlowJo, Ashland, OR).
Transwell migration assay
Migration toward an angiogenic stimulus was evaluated by the use of a transwell migration 
assay. Fluoroblok 8 μm transwell inserts (Corning, Corning, NY) were used in a 24-well 
plate. Inside the transwell were seeded with 2x105 cells, (either AECs or VECs) in 300 μl of 
EGM-2 (Lonza). The well underneath the transwell insert contained 500 μL of EGM-2 with 
an additional 50 ng/mL of VEGF (R&D Systems, Minneapolis, MN). After cells were 
incubated for 24 hrs, the transwells were fixed in 4% formaldehyde and stained with DAPI. 
The undersides of the inserts were then imaged using a Zeiss LSM 510 LIVE5 Confocal 
Microscope (Germany). Image field was 968 μm x 968 μm. Intact nuclei were counted and 
presented as means ± standard error of mean (n=3–4 biological replicates tested in 
triplicate). JMP Statistical software (SAS, Cary, NC) was used to compare difference 
between cell counts using a two-tailed Student’s t-test. P-values <0.05 were considered 
statistically significant.
Fluorescence immunocytochemical staining
To assess the in situ expression of EC and LEC markers, VECs and AECs cultured on 
gelatin coated chamber well slides (n=3 biological replicates) were fixed with 4% 
paraformaldehyde for 30 min at RT and blocked with 2 % FBS in PBS overnight at 4°C. 
Primary antibodies for CD31 (ab28364, Abcam), Flt-1 (sc-31173, Santa Cruz), CXCR4 
(ab2074, Abcam), and LYVE1 (ab33682, Abcam) were used at 1:100 dilutions in PBS and 
incubated onto samples overnight. Secondary antibodies conjugated with AlexaFluor 
488/555/633 (Invitrogen/Life Technologies) were used after primary antibody incubation. 
Fluorescent imaging was performed using a Zeiss LIVE5 Confocal Microscope.
Tissue immunohistochemical staining
Aortic valve leaflets were harvested from 10 porcine hearts purchased from commercial 
abattoirs Fisher Ham and Meats (Spring, TX) and Animal Technologies (Tyler, TX). The 
leaflets were fixed in 10% neutral buffered formalin for 3 days and subsequently dehydrated 
in increasing a series of alcohol/dH2O solutions (Flex 100, Richard Allen Scientific/Thermo 
Fisher Scientific, Waltham, MA), a 50:50 Flex:xylene (histological grade xylene, 
SigmaAldrich, St Louis, MO) solution, and finally 100% xylene. The leaflets were then 
soaked in paraffin for 3 hours at 59°C and subsequently embedded in paraffin blocks. A 
Leica RM2135 (Germany) microtome was used to section the leaflets into slices 5 μm thick 
which were mounted on glass slides. Primary antibodies for CD31 (ab119341, Abcam) and 
LYVE1 (ab33682, Abcam) were used at 1:100 dilutions in 0.5% BSA in PBS and incubated 
at room temperature for 3 hours. Secondary antibodies conjugated with AlexaFluor 488/568 
(Invitrogen/Life Technologies) were incubated for 1 hour at room temperature. Slides were 
sealed with Fluoromount-G (Southern Biotech, Birmingham, AL). Fluorescent imaging was 
performed using a Zeiss LIVE5 Confocal Microscope. Chromogenic immunohistochemical 
staining (Connell et al. 2015) was used to provide confirmation for the staining of LYVE1, 
as well as to demonstrate another LEC marker, Prox1 at a dilution of 1:100. To provide 
microstructural context for the immunostaining, additional tissue sections were stained with 
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MOVAT pentachrome as previously described(Connell et al. 2015). Leaflets from 4 hearts 
were used for immunofluorescent staining, whereas leaflets from the other 6 hearts were 
used for immunohistochemical and MOVAT staining.
Results
Demonstration of angiogenic phenotypic characteristics
Flow cytometry analysis demonstrated that VECs expressed almost double the amount of 
Flt-1 compared to AECs, 74% vs. 38% respectively (Fig. 1A). Angiogenic EC markers 
CXCR4 and DLL4 both showed over 90% expression on AECs whereas VECs showed 
much lower levels, with only 35% CXCR4+ and 47% DLL4+, indicating a less angiogenic 
phenotype. Immunofluorescent staining also verified high expression of CXCR4 and low 
expression of Flt-1 in AECs and the opposite result in VECs (Fig. 1B). Pan-endothelial 
marker CD31 expression was consistently high (90% +) in both cell populations, indicating 
the high level of EC purity post isolation and sorting.
Migration toward angiogenic stimulus
To compare the migratory potential of the AECs and VECs, a transwell assay was performed 
utilizing VEGF as the migratory signal (Fig. 2). After 24 hrs, the AECs demonstrated 
significantly greater migration with a mean of 71.5±11.0 cells per image field while the 
mean number of VECs per image field was 30.0±15.3, p=0.032. The behavioral difference 
between the two populations corresponded to the high expression levels of angiogenic/tip 
ECs markers found on the AECs and the lower levels of the same markers, as well as the 
high expression of Flt-1, on the VECs.
Demonstration of lymphatic endothelial phenotypic characteristics
For further characterization of the molecular and behavioral phenotype of VECs, the 
possibility of EC heterogeneity was considered. Both cell types were examined for 
expression of lymphatic EC markers LYVE1 and Prox1 (Fig. 3A). An appreciable 
population of VECs, approximately 30%, was LYVE1+/Prox1+; whereas these markers 
were not present in AECs. Immunofluorescent staining verified the difference in LYVE1 
expression between VECs and AECs (Fig. 3B). Another well-established lymphatic marker, 
Flt-4/VEGFR3, was not expressed on either the VECs and AECs (data not shown), but it is 
likely that the lack of expression in this study was due to culture conditions not conducive to 
its expression. Flt-4 is a receptor for VEGF isoforms C and D (Mäkinen et al. 2001) and 
EGM-2 medium only contains VEGF isoform A.
Localization of lymphatic characteristics within valvular tissue
The distribution of LECs on the surface of valves appears to correspond to the location of 
VECs (Fig. 4). Chromogenic staining of LYVE1 (Fig. 4B and C), as well as fluorescent 
staining of CD31 and LYVE1 (Fig.4F) showed that they co-localize together on the valve 
surface with both markers showing the strongest signal along the ventricularis. Chromogenic 
staining for Prox1 showed expression throughout the entire leaflet (Fig. 4D and E).
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Discussion
Although VECs demonstrate the capacity to transdifferentiate into a mesenchymal 
phenotype as well as differences in osteogenic markers under stress in comparison to 
vascular ECs (Butcher et al. 2006), these valvular cells are often treated as a uniform 
population with general, pan-endothelial traits such as the expression of CD31 and von 
Willebrand factor and the production of basement membrane extracellular matrix (Balaoing 
et al. 2014). Although that generalization is not without merit, this study evaluated the 
complexities and heterogeneity unique to this cell population and showed the existence of 
two distinct populations on the valve surface endothelium: non-angiogenic VECs and LEC-
like cells. The understanding of such nuances will be fundamental to future study of normal 
and pathological heart valve function. In addition, as progress is made towards generating 
engineered tissues that are suitable for valve replacements, it becomes necessary to ensure 
that population of cells seeded within these engineered tissues represents a phenotype that 
resembles the in vivo characteristics as closely as possible. Valve cells are particularly 
challenging in this regard, since harvesting cells from a patient is considered to be extremely 
invasive if not impossible. Therefore, a suitable VEC facsimile would need to be derived 
from a different source, such as bone marrow stem cells (Rath et al. 2015), peripheral blood 
endothelial progenitor cells (EPCs), umbilical cord blood EPCs, or possibly induced 
pluripotent stem cells (IPSCs).
Pronounced expression of Flt-1, as observed here in VECs, has become a hallmark trait of 
non-angiogenic/phalanx EC, and may be a marker for the stability of the endothelial layer 
atop valves. Flt-1 appears to mitigate angiogenic signaling by serving as a sort of “trough” 
for excess VEGF (Gille et al. 2001). VECs expressed not only high levels of Flt-1, but also 
showed reduced migration towards angiogenic stimulus, both of which are traits observed in 
non-angiogenic ECs (Mazzone et al. 2009, Blancas et al. 2012). These aspects of non-
angiogenic behavior by VECs was further supported by their low-to-moderate expression of 
angiogenic EC markers CXCR4 and DLL4, which are known to play an important role in 
angiogenesis and are found on tip ECs (Hellström et al. 2007, Strasser et al. 2010). As 
expected, AECs expressed low levels of Flt-1 (Krueger et al. 2011) and high expression of 
DLL4 and CXCR4. With respect to recapitulating these VEC characteristics in a tissue 
engineered valve, future investigators could perform directed differentiation towards a non-
angiogenic EC phenotype; this approach has already been developed using embryonic stem 
cells as a source population (Blancas et al. 2012) and the scheme could be modified to 
accommodate other cell populations. Having a seeded EC population with the ability to 
remain stationery after implantation would be critical for the success of a tissue engineered 
or bioprosthetic valve. Not only will this EC population be subject to dynamic shear stresses 
from the unique blood flow environment surrounding heart valves, but the cells would also 
need the capacity to withstand potential migratory signals that could result from the 
implantation procedure itself. If the VEC stand-in population could be derived from 
autologous cells such as EPCs, the transplanted valve would have a barrier that prevents or 
minimizes immune response.
The question of whether or not lymphatic ECs exist on the outside of the leaflets in the VEC 
layer was motivated by the finding of lymphatic vessels inside of valve leaflets (Johnson and 
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Blake 1966, Kholová et al. 2013), although the function of lymphatics within heart valves 
has not been fully elucidated. As the lymphatic system transports immune system-related 
cells, it is possible that lymphatic vessels in the interior of the valves serve as a prophylactic 
measure to prevent, or subsequently combat, valve disease. Valve thickening has been 
attributed in part to changes in lymph flow (Miller 2011). Calcified areas within aortic 
valves, especially in cases of stenosis, show an increase in the number of lymphatic vessels 
and blood vessels, likely in response to inflammation (Kholová et al. 2011, Syväranta et al. 
2012). A common way to distinguish LECs from vascular ECs is by examining the 
expression of two or more known lymphatic markers co-expressed in a single population 
(Oliver 2004). Markers include LYVE1, a hyaluronan receptor,(Banerji et al. 1999) and 
Prox1, a transcription factor that is considered to be the best functional marker for LECs 
(Hong et al. 2002). A LYVE1+/Prox1+ population was found within the VECs, indicating 
the presence of Lymphatic-like cells on the outside of the valves in the VEC layer, although 
further studies are necessary to determine what role they play in normal and abnormal 
valves. The strong expression of LYVE1 on the surface, co-localized with CD31, merits 
further investigation. It is possible that the expression of LEC markers on the leaflets may 
decrease once the cells are harvested and cultured, indicating that there is an element of 
phenotype plasticity that could shed light on VEC and LEC function. A possible purpose for 
the valve LECs is that they serve as a “reserve” population of LECs that can migrate into the 
valve when needed, thereby giving a boost to an immune response to valve disease.
Another interesting finding was the expression of Prox1 throughout the entire leaflet. This 
result is consistent with in vivo lymphatic vasculature, in which Prox1 is found largely in the 
valves while LYVE1 remains in the lumen(Sabine et al. 2012). Indeed, LYVE1 is down-
regulated in fluid shear stress, which explains its expression on the lumen only(Sabine et al. 
2012), which makes it’s expression on the leaflet surface, an area known to undergo fluid 
stress, unexpected. Future studies into the expression of LYVE1 and Prox1 under shear 
stress conditions, and potentially other endothelial lineage related markers, in VECs and 
valve interstitial cells in normal and pathological states could provide more insight into the 
inflammatory response at various stages of disease progression.
In summary, the endothelial cells comprising the outer layer of the aortic valve leaflets are a 
heterogeneous population that includes LEC-like cells and minimally or non-angiogenic/
phalanx phenotypes. In the future, it will be important to assess how these cells promote 
overall valve health or are affected by valve disease. Furthermore, this VEC heterogeneity 
has implications for heart valve tissue engineering. Although this study is preliminary in 
nature, it highlights how the in vivo valve cell populations should be examined just as 
carefully as the mechanical properties of the valve leaflets in which they reside. The 
consideration of both factors is necessary for maximizing the success of bioengineered 
constructs and therapies. In heart valve therapy specifically, understanding the changes in 
composition of the valve cell populations and leaflet matrix that occur as a patient ages or as 
a result of pathological causes can shed light on how the constituents work together to form 
a functional tissue. This information would not only aid in the development of suitable 
engineered replacements, but also in how to prevent or minimize complications post-
implantation.
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AECs aortic endothelial cells
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Fig. 1. VECs display fewer pro-angiogenic markers than AECs
(A) Flow cytometry analysis of both cell populations demonstrates that AECs express higher 
levels of pro-angiogenic/tip EC markers CXCR4 and DLL4 than VECs. Representative 
results from n=3–6. Additionally, VECs express higher levels of Flt-1, which is common in 
non-angiogenic/phalanx EC as it dampens the migratory signal of VEGF. CD31 is used as a 
pan-endothelial check to ensure both populations consist of only ECs. (B) 
Immunofluorescence comparison of VEC and AEC expression of CD31, Flt-1, and CXCR4 
(representative results from n=3). Results confirm flow cytometry results. Scale bars = 50 
μm.
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Fig. 2. VECs display largely non-migratory behavior
(A) AECs demonstrated a significantly higher migration towards an angiogenic stimulus 
(EGM-2 plus an additional 50ng/ml of VEGF). *p<0.05, n=12–16. Error bars represent 
standard error of the mean. (B) Representative images of AECs and VECs that have 
migrated through the transwell membrane. Scale bar = 200 μm.
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Fig. 3. A population of LECs are present in VECs
(A) Flow cytometry analysis of lymphatic markers LYVE1 and Prox1 in AECs and VECs 
(n=3). There is a clear population of LYVE1+/Prox1+ cells in the VECs that is absent in the 
AECs. (B) Immunofluorescent stain of AECs and VECs on 1% gelatin. Cells stained with 
LYVE1 are green and DAPI stained nuclei are blue (n=3). Scale bar represents 50 μm.
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Fig. 4. LEC markers have different expression patterns on the valve leaflets
(A) MOVAT pentachrome staining depicting the layered structure of the valve leaflet 
(V=ventricularis, S=spongiosa, F=fibrosa). As seen with immunofluorescent staining, 
LYVE1 expression (red arrowheads) is localized to the endothelial layer; secondary control 
(B) and LYVE1 stain (C). Prox1 is expressed throughout all layers of the leaflet; secondary 
control (D) and Prox1 stain (E). Scale bars = 100 μm. Representative samples from n=6. (F) 
Immunofluorescent staining indicated that the LEC marker LYVE1 (green) was co-localized 
with CD31 (red) on the surface of the valves. The staining was particularly strong on the 
ventricular-facing surface (inset). Cell nuclei counterstained with DAPI (blue). Scale bar 
represents 100 μm. Representative samples from n=4.
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